| Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma MV Mateos, MT Hernández, P Giraldo, J De la Rubia, F De Arriba, ... New England Journal of Medicine 369 (5), 438-447, 2013 | 618 | 2013 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 341 | 2014 |
| Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study–a … A Sureda, C Canals, R Arranz, D Caballero, JM Ribera, M Brune, ... Haematologica 97 (2), 310, 2012 | 260 | 2012 |
| COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey P Ljungman, R de la Camara, M Mikulska, G Tridello, B Aguado, ... Leukemia 35 (10), 2885-2894, 2021 | 188 | 2021 |
| Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 … MV Mateos, MT Hernández, P Giraldo, J de la Rubia, F de Arriba, ... The lancet oncology 17 (8), 1127-1136, 2016 | 182 | 2016 |
| The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells L López-Corral, NC Gutiérrez, MB Vidriales, MV Mateos, A Rasillo, ... Clinical cancer research 17 (7), 1692-1700, 2011 | 180 | 2011 |
| Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study S Cesaro, HH Hirsch, M Faraci, J Owoc-Lempach, A Beltrame, A Tendas, ... Clinical infectious diseases 49 (2), 233-240, 2009 | 141 | 2009 |
| Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease F Sánchez-Guijo, T Caballero-Velázquez, O López-Villar, A Redondo, ... Biology of Blood and Marrow Transplantation 20 (10), 1580-1585, 2014 | 132 | 2014 |
| SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status L Lopez-Corral, ME Sarasquete, S Beà, R García-Sanz, MV Mateos, ... Leukemia 26 (12), 2521-2529, 2012 | 127 | 2012 |
| Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical … F Baron, M Labopin, D Blaise, L Lopez-Corral, S Vigouroux, C Craddock, ... Bone marrow transplantation 49 (3), 389-396, 2014 | 111 | 2014 |
| Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks EM Ocio, P Maiso, X Chen, M Garayoa, S Alvarez-Fernandez, ... Blood, The Journal of the American Society of Hematology 113 (16), 3781-3791, 2009 | 104 | 2009 |
| Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients B Paiva, NC Gutierrez, X Chen, MB Vidriales, MÁ Montalbán, L Rosinol, ... Leukemia 26 (8), 1862-1869, 2012 | 93 | 2012 |
| Biomarkers in ocular chronic graft versus host disease: tear cytokine-and chemokine-based predictive model L Cocho, I Fernández, M Calonge, V Martinez, MJ Gonzalez-Garcia, ... Investigative ophthalmology & visual science 57 (2), 746-758, 2016 | 92 | 2016 |
| In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone EM Ocio, D Fernández-Lázaro, L San-Segundo, L López-Corral, ... Leukemia 29 (3), 705-714, 2015 | 89 | 2015 |
| Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS … B Paiva, M Pérez-Andrés, MB Vidriales, J Almeida, N de Las Heras, ... Leukemia 25 (4), 697-706, 2011 | 88 | 2011 |
| Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies L López-Corral, LA Corchete, ME Sarasquete, MV Mateos, R García-Sanz, ... haematologica 99 (8), 1365, 2014 | 87 | 2014 |
| Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma G Iacoboni, G Villacampa, N Martinez‐Cibrian, R Bailén, L Lopez Corral, ... Cancer Medicine 10 (10), 3214-3223, 2021 | 85 | 2021 |
| Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study V Escamilla Gómez, V García-Gutiérrez, L López Corral, ... Bone marrow transplantation 55 (3), 641-648, 2020 | 82 | 2020 |
| Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients J Labrador, L Lopez-Anglada, E Perez-Lopez, FS Lozano, L Lopez-Corral, ... haematologica 98 (3), 437, 2013 | 79 | 2013 |
| Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis B Paiva, MV Mateos, LI Sanchez-Abarca, N Puig, MB Vidriales, ... Blood, The Journal of the American Society of Hematology 127 (9), 1151-1162, 2016 | 72 | 2016 |
